Showing 1 posts of 1 posts found.
Novartis has pulled back the curtain on new Phase 2b data for its IgE/FceR1 pathway-blocking drug ligelizumab, showing that the …
NICE recommends daratumumab quadruplet for newly diagnosed multiple myeloma
AstraZeneca’s Trixeo approved in EU for asthma
Amplio reports early human data for novel methotrexate approach in rheumatoid arthritis
Survodutide delivers up to 13.1% weight loss in phase 3 obesity and diabetes trial
ESTEVE CDMO adds $17.5m to Illinois expansion